SMMT - Summit Therapeutics Inc. Kompaniya Profili

(SMMT)

0.00

0.00 (0.00%)

Kompaniya haqida

Summit Therapeutics Inc., biotexnologik kompaniya, bemorlar, shifokorlar, parvarishlovchilar va jamiyat uchun qulay dori vositalarini kashf qilish, ishlab chiqish va tijoratlashtirishga qaratilgan. Uning yetakchi ishlanma nomzodi ivonescimab hisoblanadi, bu immunoterapiya uchun bispesifik antitel bo'lib, PD-1 blokirovkalash va kichik hujayrali bo'lmagan o'pka rakini (NSCLC) va kolorektal rakni (CRC) davolash uchun anti-angiogenez bilan birgalikda ishlaydi. Kompaniya, shuningdek, ivonescimabni kimyoterapiya bilan birlashtirgan, bu epidermal o'sish omilining retseptor mutatsiyali, mahalliy rivojlangan yoki metastatik bo'lmagan skuamoz bo'lmagan NSCLC bemorlari uchun III bosqich klinik sinovda; birinchi qator metastatik NSCLC; va birinchi qator rezektsiya qilinmaydigan metastatik CRC uchun. Kompaniya o'z mahsulotlarini Qo'shma Shtatlar, Kanada, Yevropa, Yaponiya, Lotin Amerikasi, Yaqin Sharq va Afrikada sotadi. Kompaniya 2003 yilda tashkil etilgan va shtab-kvartirasi Mayami, Florida shahrida joylashgan.

Asosiy rahbarlar

Ism	Lavozim
Dr. Allen S. Yang M.D., Ph.D.	Head of R&D Strategy
Dr. Mahkam Zanganeh D.D.S., M.B.A.	Co-CEO, President & Director
Dr. Urte Gayko Ph.D.	Chief Regulatory, Quality & Pharmacovigilance Officer
Dr. Wang Clow Fong ScD	Chief Biometrics Officer
Mr. Bhaskar Anand	Chief Accounting Officer
Mr. Dave Gancarz	Chief Business & Strategy Officer
Mr. Manmeet Singh Soni CPA	COO, CFO & Director

Sana	Turi	Hujjat
2026-01-29	8-K	smmt-20260129.htm
2026-01-12	8-K	smmt-20260112.htm
2025-11-07	8-K	smmt-20251107.htm
2025-10-29	S-3ASR	d79902ds3asr.htm
2025-10-22	8-K	d274712d8k.htm
2025-10-20	8-K	smmt-20251017.htm
2025-09-08	8-K	smmt-20250907.htm
2025-08-11	8-K	smmt-20250811.htm
2025-06-20	8-K	smmt-20250616.htm
2025-06-17	8-K	smmt-20250612.htm

Sana

Turi

Hujjat

2026-01-29

8-K

smmt-20260129.htm

2026-01-12

8-K

smmt-20260112.htm

2025-11-07

8-K

smmt-20251107.htm